CDKN2A and neoplasm: Mutations in Nf1 and Ink4a/Arf are commonly found in ERMS tumors (15% and 4%, respectively), and this genetic combination follows the familiar pattern of Ras-pathway mutation coupled with the loss of a tumor suppressor that is found in other commonly-used RMS models [10,23,24].